{
  "harness": "sj-harness 0.3.0",
  "job": "job:7c2d6b93c28461361df2c12e9378cab4",
  "kind": "adversarial_review",
  "bundle": "sha256:dccee571f57531123726eaeb9dcd13015ac7b9160fe296eb0af674c1d286bd0d",
  "claims": [
    {
      "local_id": "C1",
      "claim_id": "claim:5196941d46c10c2d707a3ed67c6487eabcb252f3fbb58910fd18ff987f9d5dbc",
      "verdict": "minor_issues",
      "significance": "minor",
      "reason": "Reproduces exactly and the estimate is correctly reported, but the null is uninformative: minimum detectable effect about 5 per 100k on a 9.1 baseline, well above published NAL effects; 47 of 53 dropped cells were classifiable as non-dominant (suppressed T40.4 count 1-9 with 20+ opioid deaths) and drops fall heavily on treated states HI, ND, WY, VT, ID; outcome-defined moderator; TWFE under staggered adoption; second registration after seeing crude-rate results (disclosed)."
    }
  ]
}